April 3rd 2025
The study stated early recognition and aggressive treatment of childhood-onset MMP are essential to prevent permanent scarring.
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
FDA issues new warning on asthma drug Xolair
March 5th 2007Washington - The Food and Drug Administration (FDA) has issued a new warning about omalizumab, an asthma drug marketed by Genentech as Xolair, and has requested that the manufacturer add “black box” warnings to the product’s label reflecting the risk of anaphylaxis.
'Active' moisturizers key to happier skin
March 1st 2007Pittsburgh - New "activated" moisturizers help the skin retain moisture, and they also repair abnormalities with the skin at baseline in atopic dermatitis patients, according to Douglas W. Kress, M.D., of Children's Dermatology Services at Children's Hospital of Pittsburgh.
Stiefel acquisition marries technology, marketing
March 1st 2007Coral Gables, Fla. - Stiefel Laboratories' recent purchase of Connetics blends Connetics' innovative vehicle technology with Stiefel's worldwide marketing reach, company officials say. For dermatologists and patients, the acquisition augurs a steady stream of new applications for vehicles including the popular, patient-friendly foam pioneered by Connetics.
New drugs' OK process lengthy, costly
February 1st 2007National report - The Food and Drug Administration's role is a necessary one, dermatologists say, but regulatory red tape can slow the introduction of new drugs into the marketplace, and post-marketing restrictions can hamper efforts to deliver effective medications to patients.
'Fishy' symptoms should spur referral
February 1st 2007Omaha, Neb. - A patient presenting to a primary care physician with complaints of an arm rash may not be particularly unusual, but one unusual case illustrates the need for proactive cooperation between primary care physicians and specialists to best serve the patient's needs.
Be aware of lidocaine allergic contact dermatitis
February 1st 2007National report - As use of lidocaine for injectable local and topical anesthesia is increasing, dermatologists need to recognize that this amide anesthetic has the potential to cause allergic contact dermatitis, according to James Taylor, M.D., a dermatologist at The Cleveland Clinic Foundation, Cleveland.
French researchers suggest link between infant phototherapy and childhood skin moles
January 9th 2007Paris - According to a French study reported in the December issue of Archives of Dermatology, infants who received phototherapy for jaundice appear to have an increased risk of developing skin moles in childhood.